A substantially pure fluazuron and preparation thereof

WO2024241082A1PCT designated stage expired Publication Date: 2024-11-28HIKAL
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2023/055368
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-25
Publication Date
2024-11-28

Smart Images

  • Figure IB2023055368_28112024_PF_FP_ABST
    Figure IB2023055368_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to substantially pure Fluazuron. The substantially pure Fluazuron comprises one or more impurities selected from di-pyridine impurity, diamide impurity and dimer impurity. The present invention further relates to a process for the preparation of substantially pure Fluazuron of formula (I) with purity greater than 99.5% comprising one or more impurities selected from di-pyridine impurity of formula (1) less than 0.15%, diamide impurity of formula (2) is less than 0.15%, and dimer impurity of formula (3) less than 0.2% as measured by HPLC. Formula (I), Formula (1), Formula (2), Formula (3).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] “A SUBSTANTIALLY PURE FLUAZURON AND PREPARATION THEREOF”

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to substantially pure Fluazuron. The substantially pure Fluazuron comprises one or more impurities selected from di-pyridine impurity, diamide impurity and dimer impurity. The present invention further relates to a process for the preparation of substantially pure Fluazuron.

[0004] BACKGROUND OF THE INVENTION

[0005] Fluazuron is chemically known as A-[[4-chloro-3-[3-chloro-5-(trifluoromethyl) pyridin- 2-yl] oxyphenyl] carbamoyl] -2, 6-difluorobenzamide. Fluazuron is an acarine growth regulator belonging to the group of benzoyl-phenyl-urea’s. Fluazuron is an organofluoride acaricide, an organochlorine acaricide, a member of monochlorobenzenes, a N-acylurea, a chloropyridine, an aromatic ether and a member of phenyl urea’ s. It was discovered by Ciba Geigy and developed by Novartis Animal Health to control ticks on livestock, especially cattle.

[0006] Several patent publications such as US4677127A, JP58072566 A, EP0230400A2, CN101209992, CN101906070A, CN104876859B and various publications such as, J. Org. Chem. 1962, 27, 10, 3741-3744, J. Agr. Food Chem. 21, 348 and 993; 1973, Zhejiang Huagong, Volume: 45, Issue 4, Pages: 5-6, have disclosed the preparation of Fluazuron and / or its intermediates.

[0007] In recent years, the use of the Fluazuron in an injectable formulation associated with Avermectins is found to be innovative and has important technological and functional advancement for veterinary medicine. So, in near future there may arise a need for similar or other formulations which contains Fluazuron alone or in combination.

[0008] Regulatory authorities requires that the drug manufacturers including veterinary drugs to isolate, identify and characterize the impurities in their products. Furthermore, it is required to control and ensure the lowest possible level of impurities in the final drug compound, even if impurities are not identified. To comply the regulatory requirements and to prepare desired formulation(s) it is essential to prepare substantially pure active ingredient which is free from impurities. The purity of active ingredient is even more important when the drug is administered as an injectable formulation.

[0009] The impurities can be controlled or managed to a great extent by understanding the chemical structures and synthetic pathways, and particularly by identifying the parameters that influence the number of impurities in the final product.

[0010] The synthetic routes described in prior arts for the preparation of Fluazuron and / or its intermediates suffer from disadvantages mainly such as: i) having more number of impurities present in active ingredient; ii) use of toxic and harmful reagent such as phosgene gas, di and triphosgene; iii) troublesome operations, cryogenic condition; iv) involve an expensive base i.e, l,4-diazabicyclo[2.2.2]octane; v) use of expensive catalyst l-Butyl-3-methylimidazolium hexafluorophosphate; vi) low yield and purity.

[0011] Generally, the efforts in achieving high purity of Fluazuron may result in lower yield there by increasing the cost. However, the inventors of the present invention developed a process which minimizes the formation of process impurities along with high purity and greater yield.

[0012] The inventors of the present invention have developed a process for preparation of substantially pure Fluazuron by controlling the formation of impurities in reaction level itself.

[0013] SUMMARY OF THE INVENTION

[0014] In one aspect, the present invention provides a substantially pure Fluazuron of formula (I).

[0015] In another aspect, the present invention provides a substantially pure Fluazuron comprising one or more impurity(es) selected from di-pyridine impurity of formula (1), diamide impurity of formula (2), and dimer impurity of formula (3).

[0016] In another aspect, the present invention provides a substantially pure Fluazuron having purity greater than 99% comprising di-pyridine impurity less than 0.15%, diamide impurity less than 0.15%, and dimer impurity less than 0.2% as measured by HPLC.

[0017] In another aspect, the present invention relates to process for the preparation of substantially pure Fluazuron having one or more impurity(es) selected from di-pyridine impurity, diamide impurity, and dimer impurity comprising the steps of: a) preparing 4-chloro-3-((3-chloro-5-(trifluoromethyl) pyridin-2-yl) oxy) aniline (IV) by reacting 5-amino-2-chlorophenol (II), with 2-halo,3-chloro-5-(trifluoromethyl) pyridine (III) w herein in presence of base, catalyst, and solvent to obtain 4-chloro-3-((3-chloro-5- (trifluoromethyl) pyridin-2-yl) oxy) aniline (IV) having a di-pyridine impurity of formula (1); b) reacting 4-chloro-3-((3-chloro-5-(trifluoromethyl) pyridin-2-yl) oxy) aniline (IV) with 2,6-difluorobenzoyl isocyanate (VI) in solvent to obtain Fluazuron comprising one or more impurity(es) selected from di-pyridine impurity of formula (1), diamide impurity (2) and dimer impurity of formula (3); wherein 2,6-difluorobenzoyl isocyanate (VI) is prepared by reacting 2,6-difluorobenzamide (V) with oxalyl chloride in solvent to obtain 2,6-difluorobenzoyl isocyanate (VI) having diamide impurity formula (2) at a temperature for suitable time, c) purifying Fluazuron of step (b) in solvent to obtain substantially pure Fluazuron. In another aspect, the present invention relates to a process for the preparation of 2,6- difluorobenzoyl isocyanate (VI) having diamide impurity formula (2) comprising the steps of: i) reacting 2,6-difluorobenzamide (V) with 1.1 to 1.5 mol eq. of oxalyl chloride at temperature 25°C to 35°C for 1-3 hrs; ii) raising temperature of step (i) reaction mixture from 35 °C to 75 °C and maintaining for 2-3 hrs.

[0018] In another aspect, the present invention relates to a process for purification of Fluazuron to obtain substantially pure Fluazuron having one or more impurity(es) selected from dipyridine impurity (1), diamide impurity (2), and dimer impurity (3) comprising the steps of: i) dissolving Fluazuron in solvent, ii) isolating substantially pure Fluazuron.

[0019] Fluazuron, resulted using the process as defined above is substantially pure having purity greater than 99.5% comprising di-pyridine impurity (1) less than 0.15%, diamide impurity (2) less than 0.15%, and dimer impurity (3) less than 0.2% as measured by HPLC.

[0020] DETAILED DESCRIPTION OF THE INVENTION

[0021] The present invention now will be described in more detail hereinafter. The invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. As used in the specification, and in the appended claims, the singular forms “a”, “an”, “the”, include plural referents unless the context clearly indicates otherwise.

[0022] The term solvent used herein refers to the single solvent or mixture of solvents. The term “reference standard” herein after relates to a compound that may be used both for quantitative and qualitative analysis of an active pharmaceutical ingredient. For example, the retention time of the compound in HPLC allows for setting a relative retention time, thus making qualitative analysis possible. The concentration of the compound in solution before injection into an HPLC column allows for comparison of the areas under the peaks in an HPLC chromatogram, thus making quantitative analysis possible.

[0023] The term “reference marker” herein after is used in qualitative analysis to identify components of a mixture based upon their position, e.g., in a chromatogram or on a Thin Layer Chromatography (TLC) plate. A “reference marker” is used only for qualitative analysis, while a “reference standard” may be used for quantitative or qualitative analysis, or both.

[0024] The term “substantially pure” used herein, refers to the purity of compound greater than 99%, preferably greater than 99.5%, more preferably greater than 99.8% as measured by HPLC.

[0025] The term “substantially free” used herein, refers to a substantial percentage of one or more impurity(es) as measured by HPLC.

[0026] The substantial percentage used herein refers to a maximum acceptable percentage by the regulatory authority for known or unknown impurity(es).

[0027] The present invention relates to a “substantially pure Fluazuron” comprising impurities, namely:

[0028] 3-chloro-N-(4-chloro-3-((3-chloro-5-(trifluoromethyl) pyridin-2-yl) oxy) phenyl)-5-(trifluoromethyl) pyridin-2-amine impurity, designated as ‘dipyridine impurity’ and represented by compound of formula (1);

[0029] (D N-(2,6-difluorobenzoyl)-2,6-difluorobenzamide impurity, designated as ‘diamide impurity’ and represented by compound of formula (2); and Nl, N2-bis(4-chloro-3-((3-chloro-5-(trifluoromethyl) pyridin-2-yl) oxy) phenyl) oxalamide impurity designated as ‘dimer impurity’ and represented by compound of formula (3)

[0030] The instant invention provides substantially pure Fluazuron wherein the substantially pure Fluazuron is substantially free from one or more impurity(es) selected from dipyridine impurity of formula (1), diamide impurity of formula (2), and dimer impurity of formula (3).

[0031] The said ‘di-pyridine impurity ( 1 )’ is characterized by:JH NMR: (DMSO-d6, 400 MHz): 8 (ppm): 9.2 (s,lH), 8.63 (d,lH), 8.53-8.54 (d,lH), 8.49 (d,lH), 8.24 (d,lH), 7.89 (d,lH), 7.69-7.72 (dd,lH), 7.55 -7.57(d,lH); LCMS: 500 [M-H]; and HPLC purity 96.6%.

[0032] The said ‘diamide impurity (2)’ is characterized by:1H NMR: (DMSO-d6, 400 MHz): 6 (ppm): 12.38 (s, 1H), 7.58-7.66 (m, 2H), 7.22-7.27 (m, 4H); LCMS: 298 [M+H]; and HPLC purity 95.5%.

[0033] The said ‘dimer impurity (3)’ is characterized by: ' H NMR: (DMSO-d6, 400 MHz): 6 (ppm): 11.15 (s, 2H), 8.64-8.65 (d, 2H), 8.54 (t, 2H), 7.95 (d, 2H), 7.84-7.87b (dd, 2H), 7.63-7.65 (d, 2H); LCMS: 699 [M-H]; and HPLC purity 98.7%. The impurities such as ‘di-pyridine impurity’, ‘diamide impurity’ and ‘dimer impurity’ are formed during the process for the preparation of Fluazuron and they are isolated in pure form using column chromatography and further characterized.

[0034] The inventors of the present invention found the formation of ‘di-pyridine impurity’ during the preparation of compound formula (IV), ‘diamide impurity’ during the preparation of compound formula (VI), ‘dimer impurity’ during the preparation of Fluazuron (I).

[0035] The presence said ‘di-pyridine impurity’ (1), ‘diamide impurity’ (2) and ‘dimer impurity’ (3) is not yet reported so far, thus there is also a need for a process which control or remove these impurities to obtain substantially pure Fluazuron which meets regulatory standard.

[0036] The inventors of present invention developed a process which does not require separate and / or multiple purification steps for removal of the said impurities and obtained a substantially pure Fluazuron in a single purification step.

[0037] The inventor of present invention moreover developed a HPLC method for determination of Fluazuron, key starting compounds / intermediates and impurities formed, which is cited as given below:

[0038] HPLC Method 1: For Determination of intermediate and compounds of formula (II), (III), (IV) and impurity (1).

[0039] Instrument: High performance liquid chromatography equipped with UV detector / PDA detector, (Thermo scientific and Agilent).

[0040] Chromatographic conditions:

[0041] Table 1:

[0042] Gradient elution program (values in volume %):

[0043] Mobile Phase Preparation:

[0044] Buffer solution: prepare a homogenous mixture of 0.01M (1.15g / L), ammonium dihydrogen phosphate in water, sonicate for 3 minutes at ambient temperature to dissolve and filter.

[0045] Mobile phase A: mixture of Buffer solution and acetonitrile in ratio (70:30) v / v.

[0046] Mobile phase B: mixture of Buffer solution, methanol, and acetonitrile in ratio (20:27:53) v / v / v.

[0047] Diluent: mixture of acetonitrile and water in ratio (80:20) v / v.

[0048] HPLC analysis:

[0049] Table: 2

[0050] HPLC method 2: For Determination of Fluazuron compound of formula (I), (V) and impurity (2), and impurity (3).

[0051] Instrument: High performance liquid chromatography equipped with UV detector / PDA detector, (Thermo scientific and Agilent).

[0052] Chromatographic conditions:

[0053] Table 3:

[0054] Gradient elution program (values in volume %):

[0055] Mobile Phase Preparation:

[0056] Buffer solution: prepare a homogenous mixture of 0.01M (1.15g / L), ammonium dihydrogen phosphate in water, sonicate for 3 minutes at ambient temperature to dissolve and filter.

[0057] Mobile phase A: mixture of Buffer solution and acetonitrile in ratio (75:25) v / v.

[0058] Mobile phase B: mixture of Buffer solution, methanol and acetonitrile and Iso-propyl alcohol in ratio (20:20:40:20) v / v / v / v.

[0059] Diluent: mixture of acetonitrile and methanol in ratio (50:50) v / v.

[0060] HPLC analysis:

[0061] Table: 4

[0062] The present invention is more broadly elaborated in following embodiment. In one embodiment, the instant invention provides substantially pure Fluazuron of formula (I) having di-pyridine impurity of formula (1) less than 0.15%; preferably less than 0.1%.

[0063] In an embodiment the instant invention provides substantially pure Fluazuron of formula (I) having diamide impurity of formula (2) less than 0.15%; preferably less than 0.05%.

[0064] In an embodiment the instant invention provides substantially pure Fluazuron of formula (I) having dimer impurity of formula (3) less than 0.2%; preferably less than 0.1%.

[0065] In an embodiment the instant invention provides the preparation of Fluazuron of formula (I), wherein the compound of formula (VI) or its ester is not isolated, which make the present process economic and industrially feasible.

[0066] In another embodiment of the instant invention where, the base is selected from potassium carbonate, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium bicarbonate and the like.

[0067] In another embodiment of the invention where, the catalyst is selected from tetra butyl ammonium iodide, tetra-butyl ammonium bromide, tetra-butyl ammonium chloride and the like.

[0068] In another embodiment of the invention where, the preparation compound of formula (IV) is performed at temperature 80°C to 105 °C.

[0069] In another embodiment of the invention where, solvent used in step (a) is polar aprotic solvent selected from N, V-dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), 4- Dimethylaminopyridine (DMAP), N-Methyl-2-pyrrolidone (NMP), and the like.

[0070] In another embodiment of the instant invention where, solvent used in step (b) is hydrocarbon solvent selected from xylene, toluene, hexane, cyclohexane, and the like.

[0071] In another embodiment of the instant invention where, solvent used in step (c) is ester solvent selected alcoholic solvent selected from methanol, ethanol isopropanol 2 - propanil, n-butanol or ester solvent selected from methyl acetate, ethyl acetate, isopropyl acetate; or ketonic solvent selected from acetone, methyl ethyl ketone, methyl isobutyl ketone, and cyclohexanone; or mixture thereof.

[0072] The solvent(s) used for the preparation of Fluazuron is selected having moisture content less than 0.2%.

[0073] In another embodiment of the invention where, isocyanate compound of formula (VI) is prepared and used as such for the preparation of compound formula (I).

[0074] In another embodiment of the invention where, the oxalyl chloride is used in 1.1 to 1.5 mole equivalent with respect to 2,6-difluorobenzamide formula (V).

[0075] In another embodiment of the instant invention where, the preparation of an isocyanate of formula (VI) is performed by gradual temperature rising to control the diamide impurity of formula (2) and di- benzamide impurity of formula (4).

[0076] (2) (4)

[0077] Diamide Impurity Dibenzamide Impurity

[0078] In another embodiment of the instant invention where, the preparation of isocyanate of formula (VI) is carried out at 25 °C to 75 °C.

[0079] In another embodiment of the present invention, the preparation and purification of Fluazuron (I) is performed at temperatures 20°C to 75 °C.

[0080] The substantially pure Fluazuron is isolated, e.g., by decantation, filtration, centrifugation, preferably by filtration, and then optionally washing with solvent in which it was dissolved.

[0081] In another embodiment of the invention where, the substantially pure Fluazuron formula (I) qualify ICH Q3C for OVI content, having assay >99%, HPLC purity >99% along with dipyridine impurity of formula (1) < 0.15%, diamide impurity of formula (2) < 0.15 % and dimer impurity of formula (3) < 0.2%; and single maximum unknown impurity < 0.2%. In another embodiment of the invention wherein, the dipyridine impurity of formula (1), diamide impurity of formula (2) and dimer impurity of formula (3) are used as reference marker to analyze the purity of Fluazuron and as reference standard to quantify the amount of these impurities in a sample of Fluazuron.

[0082] The process for the preparation of substantially pure Fluazuron of formula (I) is illustrated in the following synthetic scheme:

[0083] The preparation of the starting materials and reagents used in the present invention are well known in prior art.

[0084] The invention is further illustrated by the following examples, which should not be construed to limit the scope of the invention in anyway.

[0085] EXPERIMENTAL

[0086] Example- 1: Preparation of compound of formula (IV)

[0087] In round bottom flask (RBF), N, A-dimethyl formamide (DMF, 3-6 Vol), 5-amino-2- chlorophenol (1.0 eq), potassium carbonate (1-1.5 eq) was added at 25°C to 35°C. To the reaction mixture 2,3-dichloro-5(trifluromethyl) pyridine (1-1.2 eq) was added and further heated at 80°C to 105 °C for 3-5 hrs. The completion of reaction was monitored by HPLC. After completion, the reaction mixture was cooled to 25°C to 35°C, water (10-20 Vol) added and stirred for 3 hrs. The reaction mixture was filtered and washed with water. The compound was treated with water at 45°C to 65°C to obtain compound of formula (IV, with 96% yield and HPLC purity 98.5%, and dipyridine impurity of formula (1) is 0.2% as determined by HPLC method 1).

[0088] Example-2: Preparation of compound of formula (I)

[0089] Step-1: Preparation of isocyanate compound of formula (VI).

[0090] In a RBF containing toluene (2-5 Vol), 2,6-difluorobenzamide (1.0 eq) was added at 20°C to 30°C. To this reaction mixture slowly oxalyl chloride (1.1 to 1.5 eq) was added and stirred for 1-2 hrs. The reaction mixture was heated at 55 °C to 75 °C for 1-2 hrs. The completion of reaction was monitored by HPLC. After completion, the solvent (1-2 Vol) was removed by simple distillation. The reaction mixture was cooled to 20°C to 30°C and used as such for the next step. (In-process sample the diamide impurity 1.5% as determined by HPLC method 2).

[0091] Step-2: Preparation of Compound of formula (I).

[0092] In a RBF, containing toluene solvent (2-5 Vol), compound of formula (IV, 1-1.2 eq) was added at 20°C to 30°C. This reaction mixture was added into step -1 at 20°C to 30°C. The reaction mixture was heated at 30°C to 45°C for 1-2 hrs. The completion of reaction was monitored by HPLC. After completion, methanol (2-5 Vol) was added at 20°C to 30°C stirred for 30 min. The compound was filtered and washed with methanol. The crude compound [assay~98%, wherein Compound (IV) - 0.5%, Compound (VI) - 0.1%, dipyridine impurity (1) -0.2%, diamide impurity (2) - 0.2%, and dimer impurity (3) - 0.4%] was purified in ethyl acetate (5-10 Vol) to obtain pure Fluazuron of formula (I, with 85.0% yield, assay 99.5%, and HPLC purity 99.8%) with dipyridine impurity of formula (1) 0.1%, diamide impurity of formula (2) 0.05 % and dimer impurity of formula (3) 0.05% as determined by HPLC method 2).

Claims

CLAIM:1) A substantially pure Fluazuron comprising one or more impurity(es) selected from dipyridine impurity of formula (1), diamide impurity of formula (2), and dimer impurity of formula (3).2) The substantially pure Fluazuron as claimed in claim 1, wherein the purity is greater than 99.5% as measured by HPLC.3) The substantially pure Fluazuron as claimed in claim 1, wherein the purity is greater than 99.5% comprising di-pyridine impurity less than 0.15%, diamide impurity less than 0.15%, and dimer impurity less than 0.2% as measured by HPLC.4) A process for preparation of substantially pure Fluazuron comprising the steps of: a) preparing 4-chloro-3-((3-chloro-5-(trifluoromethyl) pyridin-2-yl)-oxy) aniline (IV),by reacting 5-amino-2-chlorophenol (II),with 2-halo,3-chloro-5-(trifluoromethyl) pyridine (III)in presence of base, catalyst, and solvent to obtain 4-chloro-3-((3-chloro-5- (trifluoromethyl) pyridin-2-yl)-oxy) aniline (IV) having di-pyridine impurity of formula (1);b) reacting 4-chloro-3-((3-chloro-5-(trifluoromethyl) pyridin-2-yl)-oxy) aniline (IV) with 2,6-difluorobenzoyl isocyanate (VI) in solvent to obtain Fluazuron (I) comprising one or more impurity(es) selected from di-pyridine impurity of formula (1), diamide impurity (2) and dimer impurity of formula (3);wherein 2,6-difluorobenzoyl isocyanate (VI) is prepared by reacting 2,6- difluorobenzamide (V)with oxalyl chloride in solvent to obtain 2,6-difluorobenzoyl isocyanate (VI) having diamide impurity formula (2), c) purifying Fluazuron of step (b) in solvent to obtain substantially pure Fluazuron.5) The process as claimed in claim 4, wherein a base is selected from potassium carbonate, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium bicarbonate; and catalyst is selected from tetra butyl ammonium iodide, tetra-butyl ammonium bromide, and tetra-butyl ammonium chloride.6) The process as claimed in claim 4, wherein a 2-halo,3-chloro-5-(trifluoromethyl) pyridine of formula (III) is used in 1 to 1.2 mole eq. and a base is used in 1 to 1.5 mol eq.7) The process as claimed in claim 4, wherein the catalyst is selected from tetra butyl ammonium iodide, tetra-butyl ammonium bromide, and tetra-butyl ammonium chloride.8) The process as claimed in claim 4, wherein the oxalyl chloride is used from 1.1 to 1.5 mol eq. and the excess oxalyl chloride is removed.9) The process as claimed in claim 4, wherein the preparation of 2,6-difluorobenzoyl isocyanate (VI) is comprising steps of: i) reacting 2,6-difluorobenzamide (V) with 1.1 to 1.5 eq. of oxalyl chloride at temperature 25°C to 35°C for 1-3 hrs, ii) raising temperature of step (i) from 35°C to 75°C and maintaining for 2-3 hrs.10) The process as claimed in claim 4, wherein solvent used in a. step (a) is polar aprotic solvent selected from AW-dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), 4-Dimethylaminopyridine (DMAP), N-Methyl-2- pyrrolidone (NMP); b. step (b) is hydrocarbon solvent selected from xylene, toluene, hexane, cyclohexane; and c. step (c) is alcoholic solvent selected from methanol, ethanol isopropanol 2 - propanil, n-butanol or ester solvent selected from methyl acetate, ethyl acetate, isopropyl acetate; or ketonic solvent selected from acetone, methyl ethyl ketone, methyl isobutyl ketone, and cyclohexanone.11) The process for preparation of substantially pure Fluazuron comprising one or more impurity(es) selected from di-pyridine impurity, diamide impurity, and dimer impurity by purifying the Fluazuron comprising the steps of: i) dissolving Fluazuron in solvent, ii) isolating substantially pure Fluazuron.12) The process as claimed in claim 8, wherein solvent is ester solvent selected from methyl acetate, ethyl acetate, isopropyl acetate; or ketonic solvent selected from acetone, methyl ethyl ketone, methyl isobutyl ketone, and cyclohexanone.13) A substantially pure Fluazuron comprising a compound of formula of formula (1).14) A substantially pure Fluazuron comprising a compound of formula (2).15) A substantially pure Fluazuron comprising a compound of formula (3).

Citation Information

Patent Citations

  • Method for chemically synthesizing fluazuron

    CN101906070A

  • Fluazuron and preparing method thereof

    CN104876859A

  • Preparation method for fluazuron

    CN111039858A